Therefore, since CD40-mediated ICS induces T cell priming, agonistic CD40 antibodies should rather be used in combination regimen that offer tumour specific antigens as T cell targets or alleviate T cell suppression, like vaccination approaches or ICI respectively. The gene discussed is CD40; the disease is neoplasm.